4 not yet recruiting, 3 completed, 2 recruiting, 1 active not recruiting. 4 Phase 3, 3 Phase 4, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 4 | 3 | Not yet recruiting 2, Active not recruiting 1 |
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
Follow RSV Immunization: new trials by email Literature Review of RSV Immunization trials Research Report on RSV Immunization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China RSV AI-assisted primary care intervention - RSV Immunization | Not applicable | Not yet recruiting | Fudan University | 1500 | 2026-10-02 | 2026-10-13 |
| Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF RSVpreF - RSV Immunization, HIV | Phase 4 | Not yet recruiting | University of British Columbia | 20 | 2026-09-01 | 2026-07-09 |
| An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia Nirsevimab Respiratory Syncytial Virus monoclonal antibody - RSV Immunization | Completed | Sanofi | 257 | 2026-06-15 | 2026-08-10 | |
| RSV Immunisation Status in Queensland (Australia) Nirsevimab Respiratory Syncytial Virus monoclonal antibody - RSV Immunization | Completed | Sanofi | 1113 | 2026-05-29 | 2026-10-14 | |
| Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination Nirsevimab, Abrysvo - RSV Immunization | Phase 3 | Recruiting | Centre Hospitalier Annecy Genevois | 1000 | 2026-05-06 | 2026-05-27 |
| RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) - CAR-T Cell Therapy, RSV Immunization | Phase 4 | Not yet recruiting | The Cooper Health System | 30 | 2026-01-01 | 2025-12-22 |
| A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults Motivate Aim: CHW text message reminders and counseling, Motivate Aim: CHW text message reminders only, Activate Aim: CHW text message reminders and counseling - Older Adults Without Any Specific Clinical Condition, Social Networks | Not applicable | Recruiting | University of California, San Francisco | 750 | 2025-09-10 | 2025-09-30 |
| Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination. Abrysvo, Nirsevimab - RSV Immunization | Phase 3 | Not yet recruiting | PENTA Foundation | 1500 | 2025-09-01 | 2025-06-27 |
| Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India Nirsevimab - RSV Immunization | Phase 4 | Active not recruiting | Sanofi | 110 | 2025-07-31 | 2026-03-23 |
| Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine - RSV Immunization | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 2226 | 2024-05-13 | 2026-10-05 |
| Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life Nirsevimab - RSV Immunization, Healthy Volunteer | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 8057 | 2022-08-08 | 2025-10-09 |
Respiratory Tract Infections (1)
Infections (1) · Respiratory Tract Diseases (1)
nirsevimab (4) · abrysvo (2) · Chickenpox Vaccine (1) · Counseling (1) · Hepatitis B Vaccines (1) · Herpes Zoster Vaccine (1) · Measles-Mumps-Rubella Vaccine (1) · Pneumococcal Vaccines (1) · Poliovirus Vaccines (1) · Recombivax HB (1) · RotaTeq (1) · Rotavirus Vaccines (1) · Tetanus Toxoid (1) · Vaxelis (1) · YM 534 (1)
Sanofi (3) · Sanofi Pasteur, a Sanofi Company (2) · Centre Hospitalier Annecy Genevois (1) · Fudan University (1) · PENTA Foundation (1) · The Cooper Health System (1) · University of British Columbia (1) · University of California, San Francisco (1)
United States (3) · France (2) · Australia (1) · Czechia (1) · Germany (1) · India (1) · Mexico (1) · Puerto Rico (1) · United Kingdom (1)
Carina Marquez, MD (1) · Pierre Frange (1)
2025 (2), R01MD019749 (1)